IRIS
TENTORI, LUCIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 53.549
EU - Europa 6.302
AS - Asia 4.910
SA - Sud America 622
Continente sconosciuto - Info sul continente non disponibili 240
AF - Africa 69
OC - Oceania 10
Totale 65.702
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 53.328
SG - Singapore 2.369
IT - Italia 2.065
CN - Cina 1.089
DE - Germania 765
UA - Ucraina 737
RU - Federazione Russa 546
FR - Francia 516
BR - Brasile 497
IE - Irlanda 427
HK - Hong Kong 399
VN - Vietnam 345
SE - Svezia 273
GB - Regno Unito 250
PL - Polonia 247
FI - Finlandia 218
JP - Giappone 152
KR - Corea 147
CA - Canada 122
BD - Bangladesh 107
NL - Olanda 104
IN - India 66
MX - Messico 44
ID - Indonesia 38
AR - Argentina 35
CZ - Repubblica Ceca 34
CO - Colombia 32
TR - Turchia 24
ES - Italia 23
AT - Austria 20
VE - Venezuela 19
IQ - Iraq 18
JM - Giamaica 18
BE - Belgio 17
ZA - Sudafrica 17
MY - Malesia 15
EG - Egitto 14
EC - Ecuador 13
IL - Israele 13
LT - Lituania 13
PH - Filippine 13
PK - Pakistan 13
UZ - Uzbekistan 13
BG - Bulgaria 10
CH - Svizzera 10
CL - Cile 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
AU - Australia 9
IR - Iran 9
MA - Marocco 9
EU - Europa 8
KE - Kenya 8
SA - Arabia Saudita 8
KG - Kirghizistan 7
TH - Thailandia 7
CR - Costa Rica 6
HN - Honduras 6
KZ - Kazakistan 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
JO - Giordania 5
NI - Nicaragua 5
PE - Perù 5
PS - Palestinian Territory 5
PY - Paraguay 5
AL - Albania 4
GT - Guatemala 4
MK - Macedonia 4
NP - Nepal 4
OM - Oman 4
UY - Uruguay 4
BH - Bahrain 3
DK - Danimarca 3
SY - Repubblica araba siriana 3
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
KH - Cambogia 2
LB - Libano 2
MW - Malawi 2
NG - Nigeria 2
PT - Portogallo 2
AM - Armenia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
CY - Cipro 1
DZ - Algeria 1
GD - Grenada 1
GH - Ghana 1
GN - Guinea 1
GY - Guiana 1
HT - Haiti 1
KY - Cayman, isole 1
LC - Santa Lucia 1
Totale 65.453
Salva come PNG Salva come JPEG
Città #
Woodbridge 15.644
Wilmington 12.699
Houston 12.651
Ann Arbor 1.419
Ashburn 1.286
Singapore 1.265
Fairfield 1.117
Jacksonville 665
Chandler 621
San Jose 609
Seattle 447
Beijing 405
Dublin 401
Hong Kong 391
Cambridge 376
Rome 326
Medford 312
New York 308
Council Bluffs 243
Dearborn 228
Santa Clara 220
Kraków 216
Dallas 205
Milan 170
The Dalles 160
Los Angeles 152
Lawrence 149
Tokyo 114
Mülheim 113
Ho Chi Minh City 105
Buffalo 91
Moscow 77
Hanoi 69
Helsinki 68
Menlo Park 67
Zhengzhou 67
San Diego 61
Lauterbourg 56
Chicago 53
Guangzhou 50
Atlanta 49
Boardman 48
São Paulo 47
Mountain View 42
Phoenix 37
Frankfurt am Main 35
Redwood City 35
Shanghai 35
Munich 34
Falls Church 33
Naples 33
Civitavecchia 32
Denver 32
Nuremberg 32
San Francisco 32
Toronto 32
Columbus 31
San Mateo 28
London 27
Palo Alto 26
University Park 26
Brooklyn 25
Nanjing 25
Turin 25
Bari 22
Hefei 22
Montreal 22
Prague 22
Verona 22
Jakarta 21
Palermo 21
Catania 20
Florence 20
Norwalk 19
Orem 19
Ottawa 18
Rio de Janeiro 17
Bologna 16
Kansas City 16
Boston 15
Brescia 15
Brussels 15
Da Nang 15
Mexico City 15
Kunming 14
North Bergen 14
Philadelphia 14
Porto Alegre 14
Saint Petersburg 14
Stockholm 14
Johannesburg 13
Kingston 13
Nanchang 13
Redondo Beach 13
Warsaw 13
Brasília 12
Danville 12
Napoli 12
Tashkent 12
Belo Horizonte 11
Totale 55.057
Salva come PNG Salva come JPEG
Nome #
Gli inibitori della poli (ADP-ribosio) polimerasi (PARP) per superare la chemioresistenza a metilanti e inibitori di topoisomerasi I 1.616
L’attività fisica come terapia complementare: l’esempio delle malattie oncologiche 792
Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity 659
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? 622
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1 555
Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of αvβ5 integrin. 542
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells 524
Targeted therapy for brain tumours: role of PARP inhibitors 519
Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL) 515
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells 512
Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth 501
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib 499
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells 496
A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells 495
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 493
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site 491
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes 490
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity 488
Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin 485
Challenging resistance mechanisms to therapies for metastatic melanoma 485
Chemical xenogenization: antigenic changes of cancer cells induced by triazene compounds 484
Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid 480
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. 479
New aspects of immune responses against mycobacteria: immunopharmacology studies 478
Pharmacological strategies to increase the antitumor activity of methylating agents 474
Immunopharmacology of antitumor agents. 474
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma 474
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds 473
Exploiting Microglial Functions for the Treatment of Glioblastoma 471
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 469
Una medicina che cambia: l’approccio all’ipercolesterolemia. 469
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma 468
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes 467
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. 467
Novel Glutathione S-Transferase Inhibitor Enhances Temozolomide Efficacy Against Malignant Melanoma 52nd Annual Meeting of the Italian Cancer Society. Lost in translation: bridging the gap between cancer research and effective therapies 466
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components 465
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: Influence of 3'-azido-3'-deoxythymidine 465
Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy 464
Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy 464
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine 460
Modulation of GDF11 expression and synaptic plasticity by age and training 460
Chemotherapy in hairy cell leukemia. Preliminary results of a nonaggressive regimen 458
Induction of apoptosis in thymocytes by prostaglandin E2 in vivo 458
DNA damaging agents can induce celll cycle arrest in different phases of mitosis 456
Effects of diheptyldiselenide (DDS) on human tumor cell lines and on peripheral blood mononuclear cells 454
Apoptotic and clastogenic effects of methylating agents, alone or combined with poly(ADP-ribose) polymerase inhibitor, in peripheral blood lymphocytes 454
Thymic selection of the T-cell repertoire 453
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine. 452
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding 451
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy 449
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. 449
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines 448
Monoclonal antibodies to CTLA-4 with focus on ipilimumab 448
Differentiation of Ia-reactive CD8+ murine T cells does not require Ia engagement. Implications for the role of CD4 and CD8 accessory molecules in T cell differentiation 448
Activity against melanoma of an anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody that does not hamper ligand binding 448
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. 447
VEGFR-1 derived peptide specifically inhibits PlGF and VEGF-B-induced migration of endothelial cells and in vivo angiogenesis. 447
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors 446
Role of DNA repair pathways in the control of common fragile sites expression. 446
Doping and Cancer 445
Drug-mediated increase of susceptibility of human lung cancer to NK or LAK effector cells 445
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer 445
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 444
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic coils to apoptosis induced by temozolomide 442
Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. 441
Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells 440
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 440
Acute rejection of interferon-treated leukemia cells injected into lethally irradiated syngeneic mice 439
IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3' dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vitro 437
Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen 436
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. 436
Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells 434
Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma 433
Primary cultures of microglial cells for testing toxicity of anticancer drugs. 431
Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. 431
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor 430
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. 430
Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester 429
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. 427
Pharmacological inhibition of poly (ADP-ribose) polymerase (PARP) activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells and increases temozolomide sensitivity of PARP-1 silenced melanoma cells. 427
Systemic administration of the PARP inhibitor GPI 15427 increases the anti-tumor activity of temozolomide in melanoma, glioma and lymphoma preclinical models in vivo 427
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells 427
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan against colon carcinomas 425
PARP inhibitors for cancer treatment: an update on current clinical trials. 424
Acquired hemoglobin H disease in a case of refractory anemia with excess of blasts (RAEB) evolving into acute nonlymphoid leukemia 423
In vivo anti-angiogenic potential of a peptide that inhibits VEGFR-1 homodimerization and PlGF-induced migration of endothelial cells. 422
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan and temozolomide combination against colon carcinoma 421
Inhibition of poly(ADP-ribose) polymerase (PARP) increases the therapeutic efficacy of the G-quadruplex ligand RHPS4/irinotecan combination in colon cancer xenografts 421
Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro 420
PARP-1 inhibitor: a novel approach to enhance efficacy of chemotherapy. 419
Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3 419
Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant 417
In vitro antitumor activity of 3'-desamino-3'(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds 416
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 415
Inhibition of metastasis induced by triazene derivatives in mice bearing Lewis Lung Carcinoma (3LL): role of protein kinase C 415
Involvement of the mismatch repair system in temozolomide-induced apoptosis 414
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity to temozolomide. 17th International Symposium on poly(ADP-ribosyl)ation. 413
Inhibition of endothelial cell migration by vascular endothelial growth factor receptor-1 peptides. 413
Chemopotentiation by PARP inhibitors in cancer therapy 412
Influenza di farmaci antivirali o antimicobatterici sulla proliferazione di monociti umani e sulla espressione del CD1b 411
Totale 47.298
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.154
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 134.154
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.106 0 0 0 66 32 110 95 68 106 107 76 446
2022/20231.923 202 107 61 268 115 430 163 97 180 41 176 83
2023/20241.176 100 36 81 65 109 342 86 60 47 47 65 138
2024/20253.572 139 858 398 208 136 312 150 192 350 181 323 325
2025/20265.609 407 252 776 334 490 179 601 731 665 659 238 277
2026/20272.306 402 318 1.260 326 0 0 0 0 0 0 0 0
Totale 65.702